Health
Factlen Explainer
UN General Assembly Adopts New Political Declaration, Committing $21.9 Billion Annually to End AIDS by 2030
4 sources · 25d ago
Factlen Explainer
Landmark Global Consensus Redefines Heart Failure, Updating Diagnosis and Treatment for 64 Million People
5 sources · 25d ago
Factlen Explainer
Landmark Global Consensus Redefines Heart Failure, Updating Diagnosis and Treatment for 64 Million People
5 sources · 25d ago
More in Health
Factlen ExplainerHeart Failure
Landmark Global Consensus Redefines Heart Failure, Updating Diagnosis and Treatment for 64 Million People
Cardiology Societies 40%Global Health Advocates 30%Clinical Synthesis 30%
5 sources · 25d ago
Factlen Deep DiveLong COVID
Landmark Trials Test Existing Drugs to Treat Long COVID by Targeting Inflammation and Blood Flow
Clinical Researchers 40%Patient Advocacy Groups 30%Vascular Biologists 30%
5 sources · 25d ago
Factlen Deep DiveLong COVID
Landmark Trials Test Existing Drugs to Treat Long COVID by Targeting Inflammation and Blood Flow
Clinical Researchers 40%Patient Advocacy Groups 30%Vascular Biologists 30%
5 sources · 25d ago
Contraceptive TechRegulatory Approval
FDA Approves Nexplanon for Five Years of Contraception, Up From Three
Reproductive Health Clinicians 41%Patient Advocates 35%Regulatory Authorities 24%
5 sources · 25d ago
Contraceptive TechRegulatory Approval
FDA Approves Nexplanon for Five Years of Contraception, Up From Three
Reproductive Health Clinicians 41%Patient Advocates 35%Regulatory Authorities 24%
5 sources · 25d ago
Factlen ExplainerDermatology Breakthrough
Phase 3 Trial Shows Sonelokimab Achieves Durable, Near-Complete Clearance in One-Third of Hidradenitis Suppurativa Patients
Dermatologists & Clinicians 40%Patient Advocacy Groups 35%Biotech Analysts 25%
2 sources · 25d ago
Factlen ExplainerDermatology Breakthrough
Phase 3 Trial Shows Sonelokimab Achieves Durable, Near-Complete Clearance in One-Third of Hidradenitis Suppurativa Patients
Dermatologists & Clinicians 40%Patient Advocacy Groups 35%Biotech Analysts 25%
2 sources · 25d ago
Factlen ExplainerMetabolic Health
FDA Grants Tentative Approval to First Generic Injectable Semaglutide, Signaling Future Price Competition
Generic Manufacturers 38%Originator Companies 38%Regulatory Bodies 25%
4 sources · 25d ago
Factlen ExplainerVaccine Tech
FDA Committee Unanimously Backs Moderna's mRNA Flu Shot for Older Adults
Public Health Consensus 45%Regulatory Oversight 30%Biotech Innovators 25%
3 sources · 25d ago
Factlen ExplainerVaccine Tech
FDA Committee Unanimously Backs Moderna's mRNA Flu Shot for Older Adults
Public Health Consensus 45%Regulatory Oversight 30%Biotech Innovators 25%
3 sources · 25d ago
Testosterone TherapyPolicy Decision
FDA Moves to End Warnings Linking Testosterone Therapy to Prostate Cancer and Age-Related Use
Men's Health Advocates & Urologists 45%Regulatory Authorities 35%General Medical Practitioners 20%
3 sources · 25d ago
Testosterone TherapyPolicy Decision
FDA Moves to End Warnings Linking Testosterone Therapy to Prostate Cancer and Age-Related Use
Men's Health Advocates & Urologists 45%Regulatory Authorities 35%General Medical Practitioners 20%
3 sources · 25d ago
Factlen ExplainerInfant Development
Landmark Study Links Screen Time in Under-Twos to Long-Term Developmental and Health Risks
Early Childhood Researchers 40%Parental Support Advocates 30%Public Health Officials 30%
4 sources · 25d ago
Factlen ResearchHepatitis B Cure
The Evidence Pack: How a Novel Antisense Oligonucleotide Achieves a Functional Cure in Chronic Hepatitis B
Clinical Hepatologists 40%Virology & Mechanism Researchers 30%Industry & Public Health Analysts 30%
5 sources · 26d ago
Factlen ResearchHepatitis B Cure
The Evidence Pack: How a Novel Antisense Oligonucleotide Achieves a Functional Cure in Chronic Hepatitis B
Clinical Hepatologists 40%Virology & Mechanism Researchers 30%Industry & Public Health Analysts 30%
5 sources · 26d ago
Factlen ResearchMetabolic Health
The Evidence Pack: How the First Once-Weekly Insulin is Rewriting Type 2 Diabetes Management
Endocrinologists & Clinicians 40%Drug Safety Regulators 35%Pharmaceutical Developers 25%
3 sources · 26d ago
Factlen ResearchMetabolic Health
The Evidence Pack: How the First Once-Weekly Insulin is Rewriting Type 2 Diabetes Management
Endocrinologists & Clinicians 40%Drug Safety Regulators 35%Pharmaceutical Developers 25%
3 sources · 26d ago
Factlen ExplainerNeuromodulation
The Evidence Pack: How At-Home Brain Stimulation is Rewiring the Treatment of Depression
Clinical Researchers 39%Psychiatric Practitioners 39%Device Manufacturers 22%
6 sources · 26d ago
Eczema TreatmentExplainer
FDA Approves Ebglyss for Atopic Dermatitis With Six-Injections-Per-Year Maintenance Dosing
Clinical Dermatologists 40%Patient Advocates 35%Market Analysts 25%
5 sources · 26d ago
Eczema TreatmentExplainer
FDA Approves Ebglyss for Atopic Dermatitis With Six-Injections-Per-Year Maintenance Dosing
Clinical Dermatologists 40%Patient Advocates 35%Market Analysts 25%
5 sources · 26d ago
Factlen ExplainerGlioblastoma Research
Novel Vitamin B12 Compound Crosses Blood-Brain Barrier to Target Glioblastoma Tumors
Oncology Researchers 47%Clinical Skeptics 35%Patient Advocates 18%
2 sources · 26d ago